AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32658601 — intervention group
Group type: EXPERIMENTAL
Intervention: Meconium microbiota of extremely preterm neonates (born before 28 gestational weeks)
Number of subjects: 117
Study 32658816 — intervention group
Group type: EXPERIMENTAL
Intervention: Manic phase (before treatment)
Number of subjects: 18
Study 32658816 — intervention group
Group type: EXPERIMENTAL
Intervention: Manic phase (SA analysis)
Number of subjects: 18
Study 32658816 — intervention group
Group type: EXPERIMENTAL
Intervention: Euthymic phase (post treatment)
Number of subjects: 18
Study 32658816 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 32659272 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial oxidative capacity measurement in permeabilized muscle fibers using high-resolution respirometry
Number of subjects: 12
Study 32659272 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of circadian core clock genes BMAL1 and REV-ERBα
Number of subjects: 12
Study 32659272 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of repressor clock gene PER2
Number of subjects: 12
Study 32659272 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of clock genes PER1 and PER3
Number of subjects: 12
Study 32659272 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting energy expenditure measurement
Number of subjects: 12
Study 32659272 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory exchange ratio measurement
Number of subjects: 12
Study 32659786 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids administration
Number of subjects: 3
Study 32659786 — intervention group
Group type: COMPARATOR
Intervention: Selective blockade of CXCR4
Number of subjects: 3
Study 32660310 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow capacity (CFC) classification: normal, mildly reduced, moderately reduced, severely reduced
Number of subjects: 133
Study 32660467 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy with intracorporeal anastomosis
Number of subjects: 0
Study 32660467 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy with extracorporeal anastomosis
Number of subjects: 0
Study 32660467 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery with intracorporeal anastomosis
Number of subjects: 0
Study 32660467 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery with extracorporeal anastomosis
Number of subjects: 0
Study 32660467 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32660470 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator response (BDR) in FEV1
Number of subjects: 1030
Study 32660470 — intervention group
Group type: EXPERIMENTAL
Intervention: Limit of 400 mL in BDR in FEV1
Number of subjects: 1030
Study 32660613 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment for one year
Number of subjects: 88
Study 32660619 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVIO robot-assisted UKA
Number of subjects: 33
Study 32660619 — intervention group
Group type: COMPARATOR
Intervention: MAKO robot-assisted UKA
Number of subjects: 33
Study 32660634 — intervention group
Group type: EXPERIMENTAL
Intervention: 70° arthroscope
Number of subjects: 47
Study 32660634 — intervention group
Group type: COMPARATOR
Intervention: 30° arthroscope
Number of subjects: 47
Study 32660952 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide attempt surveillance program with in-depth psychiatric evaluations for suspected suicide risk.
Number of subjects: 0
Study 32660952 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for identifying individual and population-level risk factors.
Number of subjects: 0
Study 32660952 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning techniques for developing risk prediction tools.
Number of subjects: 0
Study 32661003 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg raltegravir twice daily
Number of subjects: 43
Study 32661186 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib in combination with temozolomide (stage I)
Number of subjects: 0
Study 32661186 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib in combination with temozolomide and radiotherapy (stage II)
Number of subjects: 0
Study 32661186 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib in combination with temozolomide and radiotherapy
Number of subjects: 0
Study 32661295 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (HSCT)
Number of subjects: 0
Study 32661295 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 32661447 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplification of Positivity (AMP)
Number of subjects: 29
Study 32661447 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 29
Study 32661752 — intervention group
Group type: EXPERIMENTAL
Intervention: 670 nm photobiomodulation (PBM) delivered via a retinal laser, 12 sessions over 5 weeks, 90 seconds per treatment at settings of 25, 100 or 200 mW/cm²
Number of subjects: 21
Study 32661752 — intervention group
Group type: EXPERIMENTAL
Intervention: 670 nm photobiomodulation (PBM) delivered via a light-emitting diode (LED) device
Number of subjects: 21
Study 32661789 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual physical activity (HPA)
Number of subjects: 109
Study 32661789 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity physical activity
Number of subjects: 109
Study 32661789 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality and sleep disturbances
Number of subjects: 109
Study 32662547 — intervention group
Group type: EXPERIMENTAL
Intervention: Actionable pharmacogenomic diplotypes/phenotypes; 12 pharmacogenomic genes with 30 variants were selected.
Number of subjects: 853
Study 32662547 — intervention group
Group type: EXPERIMENTAL
Intervention: Actionable pharmacogenomic diplotypes/phenotypes for medications including tacrolimus, azathioprine, clopidogrel, warfarin, simvastatin, voriconazole, antidepressants, and proton-pump inhibitors.
Number of subjects: 853
Study 32662758 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) derived from cardiac CT
Number of subjects: 0
Study 32662758 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low BMD (<80 mg/cm³)
Number of subjects: 0
Study 32663093 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric weight management interventions; details on dosage and duration not available.
Number of subjects: 0
Study 32663093 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details not available.
Number of subjects: 0
Study 32663160 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week wearable robotic exoskeleton-assisted walking program
Number of subjects: 20
Study 32664015 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 62
Study 32664022 — intervention group
Group type: EXPERIMENTAL
Intervention: Full PTSD diagnosis with subthreshold empirical categorization
Number of subjects: 353
Study 32664022 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold PTSD diagnosis with full PTSD empirical grouping
Number of subjects: 353
Study 32664022 — intervention group
Group type: COMPARATOR
Intervention: Reference group (full PTSD diagnosis and empirical categorization)
Number of subjects: 353
Study 32664088 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cytokines and interleukins collected at admission and 24 hours after, measured using enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 600
Study 32664088 — intervention group
Group type: COMPARATOR
Intervention: Matched controls for comparison
Number of subjects: 600
Study 32664827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 1512
Study 32664827 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1512
Study 32664881 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic modified complete mesocolic excision (mCME)
Number of subjects: 250
Study 32664901 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term opioid therapy (LTOT)
Number of subjects: 554
Study 32664901 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-opioid analgesics)
Number of subjects: 554
Study 32664972 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted standing neuroprosthesis including composite flat interface nerve electrodes (C-FINEs) around the proximal femoral nerves.
Number of subjects: 1
Study 32664972 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation through nerve cuff electrodes during rehabilitation with standing and quadriceps exercises.
Number of subjects: 1
Study 32665297 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (200 mg)
Number of subjects: 36
Study 32665297 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab (for patients with high-risk pathology)
Number of subjects: 36
Study 32665314 — intervention group
Group type: EXPERIMENTAL
Intervention: High-normal eGFR (≥103.9 mL/min/1.73 m²)
Number of subjects: 15773
Study 32665314 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfiltration group
Number of subjects: 15773
Study 32665314 — intervention group
Group type: EXPERIMENTAL
Intervention: Deciles 1, 9, and 10 (eGFR <50.9, 50.9-62.7, and ≥103.9 mL/min/1.73 m²)
Number of subjects: 15773
Study 32665387 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based interventions at scale
Number of subjects: 0
Study 32665387 — intervention group
Group type: COMPARATOR
Intervention: Internal control groups
Number of subjects: 0
Study 32665393 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP Optimisation Intervention (PrEP-OI) including a PrEP Coordinator and a web-based panel management tool (PrEP-Rx)
Number of subjects: 10
Study 32665393 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP Optimisation Intervention (PrEP-OI)
Number of subjects: 10
Study 32665391 — intervention group
Group type: EXPERIMENTAL
Intervention: 2BALANCE protocol (cognitive-motor dual-task protocol)
Number of subjects: 0
Study 32665855 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative fluoropyrimidine with radiotherapy (standard treatment)
Number of subjects: 309
Study 32665955 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated Varicella Zoster Vaccine (ZV); details on dosage and duration not available
Number of subjects: 0
Study 32665955 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified); details on intervention not available
Number of subjects: 0
Study 32666050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine and nilotinib combination (vinblastine once weekly, nilotinib orally BID for 12 cycles of 28 days)
Number of subjects: 35
Study 32666050 — intervention group
Group type: COMPARATOR
Intervention: Vinblastine alone
Number of subjects: 35
Study 32666165 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 0
Study 32666401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual isotope (DI) SPECT imaging for healthy liver dosimetry
Number of subjects: 0
Study 32666401 — intervention group
Group type: COMPARATOR
Intervention: Qualitative assessment of dosimetry methods
Number of subjects: 0
Study 32666584 — intervention group
Group type: EXPERIMENTAL
Intervention: Labour induction policy
Number of subjects: 21000
Study 32666871 — intervention group
Group type: EXPERIMENTAL
Intervention: SELUTION Sustained-Limus-Release Drug-Eluting Balloon
Number of subjects: 0
Study 32666919 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-Based Intervention for Parents and Youths
Number of subjects: 0
Study 32666919 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 0
Study 32667228 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated adiponectin levels
Number of subjects: 0
Study 32667228 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32667265 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasively harvested fascia lata autograft (FLA)
Number of subjects: 22
Study 32667261 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32667729 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system (RAS) drugs
Number of subjects: 10062
Study 32667729 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 10062
Study 32667729 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS blocker monotherapy
Number of subjects: 10062
Study 32667729 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic monotherapy
Number of subjects: 10062
Study 32667729 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS blocker/diuretic combo
Number of subjects: 10062
Study 32667736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cine real-time (CRT) sequences
Number of subjects: 229
Study 32667736 — intervention group
Group type: COMPARATOR
Intervention: Segmented cine steady-state free precession sequences
Number of subjects: 229
Study 32667837 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive coercion
Number of subjects: 0
Study 32667835 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32669090 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ® PanOptix IOL (TFNT00)
Number of subjects: 44
Study 32669223 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal pharmacological treatment (OPT) including lipid lowering drugs
Number of subjects: 83867
Study 32669223 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 83867
Study 32669223 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prescription prevalence of OPT
Number of subjects: 83867
Study 32669223 — intervention group
Group type: EXPERIMENTAL
Intervention: Differences in patient and healthcare variables
Number of subjects: 83867
Study 32669223 — intervention group
Group type: EXPERIMENTAL
Intervention: Time trends in prescription prevalence of OPT
Number of subjects: 83867
Study 32669376 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib (450 mg) plus Binimetinib (45 mg)
Number of subjects: 126
Study 32669548 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 CAR T cells after lymphodepleting chemotherapy, followed by four more CAR T-cell infusions without lymphodepletion.
Number of subjects: 1
Study 32669548 — intervention group
Group type: EXPERIMENTAL
Intervention: One cycle of lymphodepletion and HER2 CAR T cells.
Number of subjects: 1
Study 32669548 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional CAR T-cell infusions with pembrolizumab.
Number of subjects: 1
Study 32669548 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 months off T-cell infusions.
Number of subjects: 1
Study 32669869 — intervention group
Group type: EXPERIMENTAL
Intervention: Vixotrigine 150 mg orally three times daily
Number of subjects: 0
Study 32669869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32670040 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Booster cognitive training program (60 hours)
Number of subjects: 6
Study 32670103 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized antidepressant therapy
Number of subjects: 0
Study 32670103 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 32670169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Number of subjects: 0
Study 32670261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass spectrometry-based method for detecting DSA subclasses
Number of subjects: 69
Study 32670261 — intervention group
Group type: COMPARATOR
Intervention: Luminex-based test for DSA detection
Number of subjects: 69
Study 32670418 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mg crocin, twice daily, for 12 weeks
Number of subjects: 50
Study 32670418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32670424 — intervention group
Group type: EXPERIMENTAL
Intervention: UGN-101 (mitomycin gel)
Number of subjects: 0
Study 32670424 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 32670599 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week heavy shoulder strengthening exercise programme (3 times weekly) targeting scapular and rotator cuff muscles
Number of subjects: 12
Study 32670599 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week heavy shoulder strengthening exercise programme
Number of subjects: 12
Study 32670600 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Fixation (IF)
Number of subjects: 235
Study 32670600 — intervention group
Group type: COMPARATOR
Intervention: Hip Arthroplasty
Number of subjects: 235
Study 32670600 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Mortality
Number of subjects: 235
Study 32670812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet supplemented with 10 g essential amino acids
Number of subjects: 81
Study 32670812 — intervention group
Group type: COMPARATOR
Intervention: Non-ketogenic diet
Number of subjects: 81
Study 32671084 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0
Study 32671084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 0
Study 32671084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32671100 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum GDF15 levels
Number of subjects: 0
Study 32671131 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat (DRV/c) for 5 days on top of interferon alpha 2b inhaling
Number of subjects: 30
Study 32671131 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha 2b inhaling alone (Control)
Number of subjects: 30
Study 32671831 — intervention group
Group type: EXPERIMENTAL
Intervention: CD20-depleting therapy (e.g., rituximab, oblinutuzumab, ofatumumab, ocrelizumab)
Number of subjects: 0
Study 32671831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose interruption of CD20-depleting therapy
Number of subjects: 0
Study 32671834 — intervention group
Group type: EXPERIMENTAL
Intervention: β-carotene
Number of subjects: 350
Study 32671834 — intervention group
Group type: EXPERIMENTAL
Intervention: KB001-A (monoclonal antibody)
Number of subjects: 350
Study 32671834 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 350
Study 32671834 — intervention group
Group type: EXPERIMENTAL
Intervention: KB001-A
Number of subjects: 350
Study 32671834 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide
Number of subjects: 350
Study 32672147 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal bipolar disorder
Number of subjects: 131
Study 32672147 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal major depression
Number of subjects: 131
Study 32672147 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective modeling in early childhood
Number of subjects: 131
Study 32672147 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diagnosis
Number of subjects: 131
Study 32672790 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess soluble fms-like tyrosine kinase 1 (sFlt-1) levels
Number of subjects: 0
Study 32673037 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic behavior therapy (TBT)
Number of subjects: 0
Study 32673037 — intervention group
Group type: COMPARATOR
Intervention: Brief behavioral activation (BA)
Number of subjects: 0
Study 32673071 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemokine Receptor 2-targeted Molecular Imaging
Number of subjects: 0
Study 32673153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy after breast cancer
Number of subjects: 1252
Study 32673170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 105
Study 32673265 — intervention group
Group type: EXPERIMENTAL
Intervention: Del Nido cardioplegia solution (DNS)
Number of subjects: 474
Study 32673265 — intervention group
Group type: COMPARATOR
Intervention: Cardi-Braun blood cardioplegia solution
Number of subjects: 474
Study 32673270 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led physical activity intervention (3-month duration, 6 biweekly video chat sessions, Fitbit Charge 3, weekly feedback)
Number of subjects: 30
Study 32673270 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires and MVPA measured using ActiGraph accelerometer at baseline, 3 months, and 6 months
Number of subjects: 30
Study 32673269 — intervention group
Group type: COMPARATOR
Intervention: Digital personal health profile only
Number of subjects: 598
Study 32673269 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention at GP or MHC
Number of subjects: 598
Study 32673269 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (both groups)
Number of subjects: 598
Study 32673274 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored website (n=50)
Number of subjects: 100
Study 32673274 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical recruitment website (n=50)
Number of subjects: 100
Study 32673385 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide/rituximab (R2)
Number of subjects: 222
Study 32673385 — intervention group
Group type: COMPARATOR
Intervention: Rituximab/chemotherapy (R-Chemo)
Number of subjects: 222
Study 32673385 — intervention group
Group type: EXPERIMENTAL
Intervention: Both R2 and R-Chemo
Number of subjects: 222
Study 32673446 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib 500 mg daily for 14 days
Number of subjects: 60
Study 32673446 — intervention group
Group type: COMPARATOR
Intervention: Placebo on day 1
Number of subjects: 60
Study 32673501 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0
Study 32673661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascyrus Medical Dissection Stent (AMDS) implantation
Number of subjects: 47
Study 32673741 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ACLF patients (n=218)
Number of subjects: 1071
Study 32673741 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable decompensated cirrhosis (UDC) patients (n=233)
Number of subjects: 1071
Study 32673741 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable decompensated cirrhosis (SDC) patients (n=620)
Number of subjects: 1071
Study 32674209 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (Opdivo) plus ipilimumab (Yervoy)
Number of subjects: 0